



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 3 June 2019

Re: Freedom of Information Request
Ref: 125- 2019

Thank you for your email and clarification dated 7th May 2019 requesting information regarding treatment figures.

The information that you require is as follows:

Please see Appendix A

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Appendix A

Please detail the number of Oncology patients treated¹ (either as a monotherapy or combination therapy) by your Trust with the stated therapies, during the 12 months **January 2018 to December 2018** inclusive.

Please note in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

	Total Number of Patients Treated (regardless of Tumour Type)	Total Number of Patients Treated:				
		Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	397	Exempt under S.40 Personal Information	45	7	268	Exempt under S.40 Personal Information
Nivolumab (Opdivo)	166	22	53	7	34	58
Ipilimumab (Yervoy)	15	Exempt under S.40 Personal Information	Exempt under S.40 Personal Information	9	0	0
Nivolumab & Ipilimumab	64	Exempt under S.40 Personal Information	43	9	0	Exempt under S.40 Personal Information
Dabrafenib (Tafinlar)	Exempt under S.40 Personal Information	0	Exempt under S.40 Personal Information	0	0	0
Cabozantinib (Cabometyx)	38	Exempt under S.40 Personal Information	0	0	0	33
Sunitinib (Sutent)	50	0	0	0	0	42
Pazopanib (Votrient)	38	0	0	0	0	37
Axitinib (Inlyta)	10	0	0	0	0	9
Atezolizumab (Tecentriq)	42	0	0	Exempt	35	Exempt

¹ Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).

				under S.40 Personal Information		under S.40 Personal Information
Sorafenib (Nexavar)	42	Exempt under S.40 Personal Information	0	0	0	0
Tivozanib (Fotivda)	27	0	0	0	0	27
Cetuximab (Erbix)	167	24	0	0	0	0
Everolimus (Afinitor)	39	0	0	0	Exempt under S.40 Personal Information	6
Vemurafenib (Zelboraf)	Exempt under S.40 Personal Information	0	0	Exempt under S.40 Personal Information	0	0
Total Number Treated (all treatments)	8572	205	129	25	815	174